The research, published in the journal Molecular Therapy, represents a paradigm shift. Unlike current treatments that focus on removing amyloid plaques, this experimental drug targets the neuronal epigenome to restore proper brain function.
“"The FLAV-27 compound represents an innovative and promising approach to Alzheimer's, with the potential to modify the disease."
The drug inhibits the G9a enzyme, which is responsible for silencing genes vital for memory and synaptic plasticity. In tests conducted by UB and CIBERNED, the compound not only reduced pathological markers but also restored cognitive function and social behavior.
Currently in advanced preclinical stages, the project led by the University of Barcelona must now undergo regulatory toxicology studies before human clinical trials can be authorized, a process expected to take several years.
